Maxi Boz II

AOR04245

Reduces osteoarthritis symptoms

  • A herb with remarkable anti-inflammatory properties
  • Supports healthy joint function
  • Helps relieve pain
  • Provides a standardized extract backed by clinical research
Gluten Free
Non-GMO
Vegan

$36.06 or subscribe and save 20%

Out of stock

Maxi Boz II is a standardized, high dose extract of the resin of Boswellia serrata. Also known as Indian Frankincense, Boswellia serrata is a botanical with a long history of use in Ayurveda, the ancient medicine system of India. It has been traditionally used to relieve inflammation, particularly of the joints. Studies have shown that boswellia reduces inflammation and pain in rheumatoid arthritis and osteoarthritis and has also been shown to be effective in reducing the severity of inflammatory intestinal disorders.

Supplementation with boswellia extract has even been shown to prevent the degradation of glycosaminoglycan, one of the major components of cartilage, which cannot be said about standard NSAID medications. Interestingly, boswellia can also be used for respiratory support, as it has been shown to reduce mucous secretions in the lungs.

Whether you are suffering from aching joints, intestinal inflammation, acute or chronic inflammation due to irritation, injury or autoimmunity, Maxi Boz II is an excellent choice to help manage inflammation and to encourage recovery.

AOR Advantage

AOR’s Maxi Boz II contains standardized Boswellia serrata to prevent and alleviate the damages caused by excessive inflammation and reduce the symptoms of inflammatory disorders such as arthritis, ulcerative colitis, and many others.

NPN

80026702

Discussion

Maxi Boz II is clinically proven to help relieve pain and swelling associated with osteoarthritis of the knee. Maxi Boz II is formulated with a standardized extract of boswellia, a botanical used in Ayurvedic medicine for support in inflammatory conditions.

Guarantees

AOR™ guarantees that all ingredients have been declared on the label. Contains no wheat, gluten, corn, nuts, peanuts, sesame seeds, sulphites, mustard, soy, dairy, eggs, fish, shellfish or any animal by product.

Adult Dosage

Take one capsule three times daily with food, or as directed by a qualified health care practitioner. Use for a minimum of two months to see beneficial effects.

Cautions

Consult a health care practitioner prior to use if you are pregnant, breastfeeding or for use beyond six months. Some people may experience mild gastrointestinal effects such as diarrhea, abdominal pain/cramps, nausea, heartburn and vomiting, or hypersensitivity (e.g. allergy); in which case, discontinue use.

Main Applications
  • Osteoarthritis
  • Anti-inflammatory
  • Asthma
  • Skin disorders
  • Inflammatory bowel disease
Disclaimer

The information and product descriptions appearing on this website are for information purposes only, and are not intended to provide or replace medical advice to individuals from a qualified health care professional. Consult with your physician if you have any health concerns, and before initiating any new diet, exercise, supplement, or other lifestyle changes.

Serving Size: One Capsule

Non-medicinal Ingredients: microcrystalline cellulose, potato starch, sodium stearyl fumarate. Capsule: hypromellose.

Anti-inflammatory Analgesic

Study #1:

Gum-resin extracts of Boswellia serrata have been traditionally used in folk medicine for centuries to treat various chronic inflammatory diseases. The resinous part of Boswellia serrata possesses monoterpenes, diterpenes, triterpenes, tetracyclic triterpenic acids and four major pentacyclic triterpenic acids i.e. β-boswellic acid, acetyl-β-boswellic acid, 11-keto-β-boswellic acid and acetyl-11-keto-β-boswellic acid, responsible for inhibition of pro-inflammatory enzymes. Out of these four boswellic acids, acetyl-11-keto-β-boswellic acid is the most potent inhibitor of 5-lipoxygenase, an enzyme responsible for inflammation.

Siddiqui MZ. Boswellia serrata, a potential antiinflammatory agent: an overview. Indian J Pharm Sci. 2011;73(3):255-261. doi:10.4103/0250-474X.93507 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3309643/

Study #2:

In vitro studies and animal models show that boswellic acids were found to inhibit the synthesis of pro-inflammatory enzyme, 5-lipoxygenase (5-LO) including 5-hydroxyeicosatetraenoic acid (5-HETE) and leukotriene B4 (LTB-4), which cause bronchoconstriction, chemotaxis, and increased vascular permeability. Other anti-inflammatory plant constituents, such as quercetin, also block this enzyme, but they do so in a more general fashion, as an antioxidant, whereas boswellic acids seem to be specific inhibitor of 5-LO. 5-LO generates inflammatory leukotrienes, which cause inflammation by promoting free radical damage, calcium dislocation, cell-adhesion, and migration of inflammation-producing cells to the inflamed body area.

Ammon HP. Salai Guggal – Boswellia serrata: from a herbal medicine to a specific inhibitor of leukotriene biosynthesis. Phytomedicine. 1996;3(1):67-70. doi:10.1016/S0944-7113(96)80012-2 https://www.sciencedirect.com/science/article/abs/pii/S0944711396800122?via%3Dihub

Study #3:

In vitro studies by Ammon et al. in 1993 also elucidated that boswellic acids were found to inhibit leukotriene synthesis via 5-LO but did not affect the 12-lipoxygenase or cyclooxygenase activities, nor did they prevent peroxidation of arachidonic acid by iron or ascorbate. Boswellic acids were, therefore, shown to be specific, non-redox inhibitors of leukotriene synthesis, either interacting directly with 5-LO or blocking its translocation. Boswellic acids have also been observed to inhibit human leukocyte elastase (HLE), which may be involved in the pathogenesis of emphysema. HLE also stimulates mucus secretion and thus may play a role in cystic fibrosis, chronic bronchitis and acute respiratory distress syndrome. HLE is a serine protease, which initiates injury to the tissues which, in turn, triggers the inflammatory process. This dual inhibitory action on the inflammatory process is unique to boswellic acids. Of these four boswellic acids, 3-acetyl-11-keto-β-boswellic acid (AKBA) is the most potent inhibitor of 5-LO, an enzyme responsible for inflammation.

Safayhi H, Sailer ER, Ammon HP. Mechanism of 5-lipoxygenase inhibition by acetyl-11-keto-beta-boswellic acid. Mol Pharmacol. 1995;47(6):1212-1216. https://molpharm.aspetjournals.org/content/47/6/1212.long

Analgesic Activity

Study #1:

In this 2014 crossover, randomized study, twelve healthy subjects were randomized (1:1) to receive single oral dose of Boswellia serrata (Shallaki®) 125 mg, two capsules or identical placebo. The researchers evaluated the analgesic activity of Boswellia serrata by using validated mechanical pain model, Ugo basile analgesymeter (by Randall Selitto test), at baseline and at one hour, two hours and three hours after test drug administration. Statistical analysis was done by paired t-test.

Mean percentage change from baseline in Pain Threshold force and time with Boswellia serrata when compared to placebo had significantly increased [Force: 9.7 ± 11.0 vs 2.9 ± 3.4 (P = 0.05) and time: 9.7 ± 10.7 vs 2.8 ± 3.4 (P = 0.04)] at third hr. Mean Percentage change from baseline in Pain Tolerance force and time with Boswellia serrata when compared to placebo had significantly (P ≤ 0.01) increased at one hour, two hours and three hours.

Conclusion: In the present study, Boswellia serrata significantly increased the Pain Threshold and Pain Tolerance force and time compared to placebo. Both study medications were well tolerated.

Prabhavathi K, Chandra US, Soanker R, Rani PU. A randomized, double blind, placebo controlled, cross over study to evaluate the analgesic activity of Boswellia serrata in healthy volunteers using mechanical pain model. Indian J Pharmacol. 2014;46(5):475-479. doi:10.4103/0253-7613.140570 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4175880/#:~:text=Conclusion%3A,analgesic%20efficacy%20of%20the%20drug.

Treatment of Osteoarthritis/Arthritis

Study #1:

A double‐blind, placebo‐controlled human trial was conducted in 2019 to evaluate the safety and efficacy of a standardized oral supplementation of Boswellin®, a novel extract of Boswellia serrata extract (BSE) containing 3‐acetyl‐11‐keto‐β‐boswellic acid (AKBBA) with β‐boswellic acid (BBA). A total of 48 patients with osteoarthritis (OA) of the knee were randomized and allocated to the BSE and placebo groups for intervention. Patients were administered BSE or placebo for a period of 120 days. The trial results revealed that BSE treatment significantly improved the physical function of the patients by reducing pain and stiffness compared with placebo. Radiographic assessments showed improved knee joint gap and reduced osteophytes (spur) confirming the efficacy of BSE treatment. BSE also significantly reduced the serum levels of high‐sensitive C‐reactive protein, a potential inflammatory marker associated with OA of the knee. No serious adverse events were reported. This is the first study with BSE conducted for a period of 120 days, longer than any other previous clinical trial on patients with OA of the knee. The findings provide evidence that biologically active constituents of BSE, namely, AKBBA and BBA, act synergistically to exert anti‐inflammatory/anti‐arthritic activity showing improvement in physical and functional ability and reducing the pain and stiffness.

Majeed M, Majeed S, Narayanan NK, Nagabhushanam K. A pilot, randomized, double-blind, placebo-controlled trial to assess the safety and efficacy of a novel Boswellia serrata extract in the management of osteoarthritis of the knee. Phytother Res. 2019;33(5):1457-1468. doi:10.1002/ptr.6338 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6681146/

Study #2:

In this 2008, double-blind, randomized, placebo-controlled study on 75 Osteoarthritis(OA) patients, the researchers evaluated the efficacy and safety of 5-Loxin in the treatment of OA of the knee over a 90-day period. 5-Loxin is a novel Boswellia serrata extract enriched with 30% 3-O-acetyl-11-keto-beta-boswellic acid (AKBA), which exhibits potential anti-inflammatory properties by inhibiting the 5-lipoxygenase enzyme.

The patients received either 100 mg (n = 25) or 250 mg (n = 25) of 5-Loxin daily or a placebo (n = 25) for 90 days. Each patient was evaluated for pain and physical functions by using the standard tools (visual analog scale, Lequesne’s Functional Index, and Western Ontario and McMaster Universities Osteoarthritis Index) at the baseline (day 0), and at days 7, 30, 60 and 90. Additionally, the cartilage degrading enzyme matrix metalloproteinase-3 was also evaluated in synovial fluid from OA patients. Measurement of a battery of biochemical parameters in serum and haematological parameters, and urine analysis were performed to evaluate the safety of 5-Loxin in OA patients.

70 patients completed the study. At the end of the study, both doses of 5-Loxin conferred clinically and statistically significant improvements in pain scores and physical function scores in OA patients. Interestingly, significant improvements in pain score and functional ability were recorded in the treatment group supplemented with 250 mg 5-Loxin as early as seven days after the start of treatment. Corroborating the improvements in pain scores in treatment groups, we also noted significant reduction in synovial fluid matrix metalloproteinase-3. In comparison with placebo, the safety parameters were almost unchanged in the treatment groups.

Conclusion: 5-Loxin reduces pain and improves physical functioning significantly in OA patients; and it is safe for human consumption. 5-Loxin may exert its beneficial effects by controlling inflammatory responses through reducing proinflammatory modulators, and it may improve joint health by reducing the enzymatic degradation of cartilage in OA patients.

Sengupta K, Alluri KV, Satish AR, et al. A double blind, randomized, placebo controlled study of the efficacy and safety of 5-Loxin for treatment of osteoarthritis of the knee. Arthritis Res Ther. 2008;10(4):R85. doi:10.1186/ar2461 https://pubmed.ncbi.nlm.nih.gov/7603462/

Study #3:

In vivo study examining the effect of Boswellia extract and ketoprofen on glycosaminoglycan metabolism showed that Boswellia considerably reduced the degradation of glycosaminoglycans compared to controls, whereas ketoprofen caused a reduction in total tissue glycosaminoglycan content. In contrast to non-steroidal antiinflammatory drugs (NSAIDS), which are well known to disrupt glycosaminoglycan synthesis, thus accelerating articular damage in arthritic conditions, boswellic acids have been shown to significantly reduce glycosaminoglycan degradation.

Siddiqui MZ. Boswellia serrata, a potential antiinflammatory agent: an overview. Indian J Pharm Sci. 2011;73(3):255-261. doi:10.4103/0250-474X.93507 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3309643/

Chronic/Ulcerative Colitis

Study #1:

Ulcerative colitis is an inflammatory disease that involves only the colon and rectum, being characterized by leukocyte infiltrate and superficial ulcers in the intestinal mucosa. To evaluate the anti-inflammatory and antioxidant effects of extract from the Boswellia serrata plant in an experimental rat model of acute ulcerative colitis induced by the administration of acetic acid (AA). An extract of B. serrata (34.2 mg/kg/day) was administered by oral gavage for two days before and after the induction of colitis with 4 mL of 4% AA. The anal sphincter pressure in the colitis group showed a significant decrease compared to that of the control groups (p < 0.001). The analysis of the values of lipid peroxidation (LPO) obtained by substances that react with thiobarbituric acid (TBARS) showed a significantly increased LPO in the colitis group compared to the control groups (p < 0.001). The nitric oxide levels and the expression of inducible nitric oxide synthase (iNOS) showed a significant increase in the colitis group compared to control groups (p < 0.01). Both pretreatment and treatment with B. serrata exhibited significantly reduced lipid peroxidation, nitric oxide and iNOS and showed improvements in tissue injury and anal sphincter pressure in animals with ulcerative colitis. The B. serrata extract has protective anti-inflammatory and antioxidant effects that inhibit inflammatory mediators in acute experimental colitis.

Hartmann RM, Fillmann HS, Martins MI, Meurer L, Marroni NP. Boswellia serrata has beneficial anti-inflammatory and antioxidant properties in a model of experimental colitis. Phytother Res. 2014;28(9):1392-1398. doi:10.1002/ptr.5142 https://onlinelibrary.wiley.com/doi/abs/10.1002/ptr.5142

Study #2:

In this 2001 clinical trial, Gupta and his colleagues studied the effects of gum resin of Boswellia serrata in patients with chronic colitis. Patients studied here suffered from chronic colitis characterized by vague lower abdominal pain, bleeding per rectum with diarrhoea and palpable tender descending and sigmoid colon. The inflammatory process in colitis is associated with increased formation of leukotrienes causing chemotaxis, chemokinesis, synthesis of superoxide radicals and release of lysosomal enzymes by phagocytes. The key enzyme for leukotriene biosynthesis is 5-lipoxygenase. Boswellic acids were found to be non-redox, non-competitive specific inhibitors of the enzyme 5-lipoxygenase.

The researchers studied the gum resin of Boswellia serrata for the treatment of this disease. Thirty patients, 17 males and 13 females in the age range of 18 to 48 years with chronic colitis were included in this study. Twenty patients were given a preparation of the gum resin of Boswellia serrata (900 mg daily divided in three doses for six weeks) and ten patients were given sulfasalazine (3 mg daily divided in three doses for six weeks) and served as controls. Out of 20 patients treated with Boswellia gum resin 18 patients showed an improvement in one or more of the parameters: including stool properties, histopathology as well as scanning electron microscopy, besides haemoglobin, serum iron, calcium, phosphorus, proteins, total leukocytes, and eosinophils. In the control group six out of 10 patients showed similar results with the same parameters. Out of 20 patients treated with Boswellia gum resin 14 went into remission while in case of sulfasalazine remission rate was four out of 10. In conclusion, this study shows that a gum resin preparation from Boswellia serrata could be effective in the treatment of chronic colitis with minimal side effects.

Gupta I, Parihar A, Malhotra P, et al. Effects of gum resin of Boswellia serrata in patients with chronic colitis. Planta Med. 2001;67(5):391-395. doi:10.1055/s-2001-15802 https://pubmed.ncbi.nlm.nih.gov/11488449/

Study #3:

In a previous study performed in 1997, Gupta and his colleagues studied the effects of Boswellia serrata gum resin in patients with ulcerative colitis (UC). UC is a chronic inflammatory disease of the colon where leukotrienes are suggested to play an important role for keeping inflammation active. Boswellic acids, the biologically active ingredients of the gum resin of Boswellia serrata (Sallai guggal), have been shown to be specific, nonredox and noncompetitive inhibitors of 5-lipoxygenase, the key enzyme of leukotriene biosynthesis. In patients suffering from ulcerative colitis grade II and III the effect of Boswellia serrata gum resin preparation (350 mg thrice daily for six weeks) on stool properties, histolopathology and scan microscopy of rectal biopsies, blood parameters including Hb, serum iron, calcium, phosphorus, proteins, total leukocytes and eosinophils was studied. Patients receiving sulfasalazine (1 g twice daily) served as controls. All parameters tested improved after treatment with Boswellia serrata gum resin, the results being similar compared to controls: 82% out of treated patients went into remission; in case of sulfasalazine remission rate was 75%.

Gupta I, Parihar A, Malhotra P, et al. Effects of Boswellia serrata gum resin in patients with ulcerative colitis. Eur J Med Res. 1997;2(1):37-43. https://pubmed.ncbi.nlm.nih.gov/9049593/

You may also like…

Select options

Bone Basics™

Supports bone health and cartilage repair

  • Helps maintain healthy bones
  • Supports joint health and cartilage repair
120 Capsules
240 Capsules
360 Capsules